ПРОГНОСТИЧЕСКОЕ ЗНАЧЕНИЕ БИОМАРКЕРОВ ПРИ ПЛОСКОКЛЕТОЧНОМ РАКЕ ПОЛОСТИ РТА. ОБЗОР ЛИТЕРАТУРЫ
https://doi.org/10.17650/2222-1468-2014-0-4-28-33
Аннотация
Достижения в понимании молекулярных механизмов, лежащих в основе развития плоскоклеточного рака полости рта (ПРПР), привели к увеличению числа молекул-биомаркеров, которые могут быть использованы для прогнозирования клинического течения данного заболевания, а также для оценки прогноза и выживаемости больных. В клинической практике определение биомаркеров опухолевых клеток ПРПР может иметь огромное значение для прогнозирования и оценки эффекта при лечении таргетными препаратами. Нами были проанализированы статьи из медицинских журналов, опубликованные в базе PubMed за последние 8 лет. Были обработаны данные исследований 24 молекулярных биомаркеров, которые были разделены на 5 групп, основанных на биологических функциях: 1) маркеры, ответственные за ускорение клеточного цикла и пролиферации; 2) гипоксия-индуцируемые факторы (hypoxia-inducible factors (HIF)); 3) маркеры супрессии и апоптоза опухолевых клеток; 4) маркеры ангиогенеза; 5) маркеры клеточной адгезии и деградации внеклеточного матрикса. Также выполнен обзор исследований, посвященных роли белковых биомаркеров, выявленных с помощью иммуногистохимических исследований, в прогнозировании исхода заболевания.
Об авторах
А. В. Игнатова
ФГБНУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН, Москва
Россия
Россия
Контакты: Анастасия Валерьевна Игнатова annasurge@gmail.com
Кафедра онкологии ГБОУ ДПО РМАПО Минздрава России; 125993, Россия, Москва, ул. Баррикадная, 2/1;
А. М. Мудунов
НИИ клинической онкологии ФГБНУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН, Москва
Россия
Россия
М. Н. Нариманов
НИИ клинической онкологии ФГБНУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН, Москва
Россия
Россия
Список литературы
1. Tilakaratne W. M., NissankaJayasuriya E. H. Value of HIF-1α as an independent prognostic indicator in oral squamous cell carcinoma. Expert Rev Mol Diagn 2011;11(2):145–7. doi: 10.1586 / erm. 11.2.
2. Massano J., Regateiro F. S., Januario G., Ferreira A. Oral squamous cell carcinoma: review of prognostic and predictive factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102(1):67–76.
3. Oliveira L. R., Ribeiro-Silva A. Prognostic significance of immunohistochemical biomarkers in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 2011;40:298–307. doi: 10.1016 / j. ijom. 2010.12.003.
4. de Vicente J. C., Lequerica-Fernandez P., Santamaria J., Fresno M. F. Expression of MMP-7 and MT1-MMP in oral squamous cell carcinoma as predictive indicator for tumor invasion and prognosis. J Oral Pathol Med 2007;36:415–24.
5. Fillies T., Woltering M., Brandt B. et al. Cell cycle regulating proteins p21 and p27 in prognostic of oral squamous cell arcinomas. Oncol Rep 2007;17:355–9.
6. Hoogsteen I. J., Marres H. A., Bussink J. et al. Tumor microenvironment in head and neck squamous cell carcinomas: prediсtive value and clinical relevance of hypoxic markers. A review. Head Neck 2007;29(6):591–604.
7. Munoz-Guerra M. F., Marazuela E. G., Fernandez-Contreras M. E., Gamallo C. P-cadherin expression reduced in squamous cell carcinoma of the oral cavity: an indicator of poor prognosis. Cancer 2005;103:960–9.
8. Myoung H., Kim M. J., Lee J. H. et al. Correlation of proliferative markers (Ki-67 and PCNA) with survival and lymph node metastasis in oral squamous cell carcinoma: a clinical and histopathological analysis of 113 patients. Int J Oral Maxillofac Surg 2006;35:1005–10.
9. Riley R. D., Sauerbrei W., Altman D. G. Prognostic markers in cancer: the evolution of evidence from single studies to metaanalysis, and beyond. Br J Cancer 2009;100:1219–29. doi: 10.1038 / sj. bjc. 6604999.
10. ICD-10. International Statistical Classification of Diseases and Related Health Problems. 10 revision. World Health Organisation: Geneva, 1997.
11. Barnett S. F., Bilodeau M. T., Lindsley C. W. The Akt / PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation. Curr Top Med Chem 2005;5(2):109–25.
12. Lim J., Kim J. H., Paeng J. Y. et al. Prognostic value of activated Akt expression in oral squamous cell carcinoma. J Clin Pathol 2005:;58:1199–205.
13. Amo Y., Masuzawa M., Hamada Y., Katsuoka K. Serum concentrations of vascular endothelial growth factor-D in angiosarcoma patients. Br J Dermatol 2004;150(1):160–1.
14. Shiraki M., Odajima T., Ikeda T. et al. Combined expression of p53, cyclin D1 and epidermal growth factor receptor improves estimation of prognostic in curatively resected oral cancer. Mod Pathol 2005;18:1482–9.
15. LaCasse E.C., Mahoney D. J., Cheung H. H. et al. IAP-targeted therapies for cancer. Oncogene 2008;27(48):6252–75.
16. Agra I. M., Carvalho A. L., Pinto C. A. et al. Biological markers and prognostic in recurrent oral cancer after salvage surgery. Arch Otolaryngol Head Neck Surg 2008;134:743–9. doi: 10.1001 / archotol. 134.7.743.
17. Laimer K., Spizzo G., Gastl G. et al. High EGFR expression predicts poor th prognostic in patients with squamous cell carcinoma of the oral cavity and oropha rynx: a TMA-based immunohistochemical analysis. Oral Oncol 2007;43:193–8.
18. Silva S. D., Perez D. E., Alves F. A. et al. ErbB2 and fatty acid synthase(FAS) expression in 102 squamous cell carcinomas of the tongue: correlation with clinical outcomes. Oral Oncol 2008;44:484–90.
19. Silva S. D., Cunha I. W., Nishimoto I. N. et al. Clinicopathological significance of ubiquitin-specific protease 2a(USP2a), fatty acid synthase(FASN), and ErbB2 expression in oral squamous cell carcinomas. Oral Oncol 2009;45:e134–e139.
20. Diniz-Freitas M., Garcia-Caballero T., Antunez-Lopez J. et al. Pharmaco diagnostic evaluation of EGFR expression in oral squamous cell carcinoma. Oral Dis 2007;13(3):285–90.
21. Smid E. J., Stoter T. R., Bloemena E. et al. The importance of immunohistochemical expression of EGFR in squamous cell carcinoma of the oral cavity treated with surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys 2006;65:1323–9.
22. Santamaria D., Ortega S. Cyclins and CDKS in development and cancer: lessons from genetically modified mice. Front Biosci 2006;11:1164–88.
23. Yu Z., Weinberger P. M., Haffty B. G. et al. Cyclin d1 is a valuable prognostic marker in oropharyngeal squamous cell carcinoma. Clin Cancer Res 2005;11:1160–6.
24. Jayasurya R., Sathyan K. M., Lakshminarayanan K. et al. Phenotypic alterations in Rb pathway have more prognostic influence than p53 pathway proteins in oral carcinoma. Mod Pathol 2005;18(8):1056–66.
25. Bullwinkel J., Baron-Luhr B., Ludemann A. et al. Ki-67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells. J Cell Physiol 2006;206(3):624–35.
26. Lee J. I., Jin B. H., Kim M. A. et al. Prognostic significance of CXCR-4 expression in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;107(5):678–84. doi: 10.1016 / j. tripleo. 2008.12.047.
27. Naryzhny S. N. Proliferating cell nuclear antigen: a proteomics view. Cell Mol Life Sci 2008;65:3789–808.
28. Kim S. J., Shin H. J., Jung K. Y. et al. Prognostic value of carbonic anhydrase IX and Ki-67 expression in squamous cell carcinoma of the tongue. Jpn J Clin Oncol 2007;37(11):812–9.
29. Koh Y., Kim T. M., Jeon Y. K. et al. Class III β-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. Ann Oncol 2009;20(8):1414–9. doi: 10.1093 / annonc / mdp002.
30. Camisasca D. R., Honorato J., Bernardo V. et al. Expression of Bcl-2 family proteins and associated clinicopathologic factors predict survival outcome in patients with oral squamous cell carcinoma. Oral Oncol 2009;45(3):225–33. doi: 10.1016 / j. oraloncology. 2008.05.021.
31. de Vicente J. C., Olay S., LequericaFernandez P. et al. Expression of Bcl-2 but not Bax has a prognostic significance in tongue carcinoma. J Oral Pathol Med 2006;35(3):140–5.
32. Kato K., Kawashiri S., Yoshizawa K. et al. Apoptosis-associated markers and clinical outcome in human oral squamous cell carcinomas. J Oral Pathol Med 2008;37:364–71.
33. Soni S., Kaur J., Kumar A. et al. Alterations of rb pathway components are frequent events in patients with oral epithelial dysplasia and predict clinical outcome in patients with squamous cell carcinoma. Oncology 2005;68:314–25.
34. Tashiro E., Tsuchiya A., Imoto M. Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer Sci 2007;98:629–35.
35. Chari N. S., Pinaire N. L., Thorpe L. et al. The p53 tumor suppressor network in cancer and the therapeutic modulation of cell death. Apoptosis 2009;14(4):336–47.
36. Lane D. P., Benchimol S. p53: oncogene or anti-oncogene? Genes Dev 1990 Jan;4(1):1–8.
37. de Oliveira L. R., Ribeiro-Silva A., Zucoloto S. Prognostic impact of p53 and p63 immunoexpression in oral squamous cell carcinoma. J Oral Pathol Med 2007;36(4):191–7.
38. Oliveira L. R., Ribeiro-Silva A., Zucoloto S. Prognostic significance of p53 and p63 immunolocalisation in primary and matched lymph node metastasis in oral squamous cell carcinoma. Acta Histochem 2007;109(5):388–96.
39. Oliveira L. R., Ribeiro-Silva A., Costa J. P. et al. Prognostic factors and survival analysis in a sample of oral squamous cell carcinoma patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;106(5):685–95.
40. Lo Muzio L., Santarelli A., Caltabiano R. et al. p63 overexpression associates with poor prognostic in head and neck squamous cell carcinoma. Hum Pathol 2005;36(2):187–94.
41. Lo Muzio L., Campisi G., Farina A. et al. Effect of p63 expression on survival in oral squamous cell carcinoma. Cancer Invest 2007;25:464–9.
42. Nemes J. A., Nemes Z., Marton I.J. p21WAF1 / CIP1 expression is a marker of poor prognostic in oral squamous cell carcinoma. J Oral Pathol Med 2005;34(5):274–9.
43. Zhang M., Zhang P., Zhang C. et al. Prognostic significance of Bcl-2 and Bax protein expression in the patients with oral squamous cell carcinoma. J Oral Pathol Med 2009;38:307–13.
44. Lippert B. M., Knauer S. K., Fetz V. et al. Dynamic survivin in head and neck cancer: molecular mechanism and therapeutic potential. Int J Cancer 2007;121(6):1169–74. 45. Lo Muzio L., Farina A., Rubini C. et al. Survivin as prognostic factor in squamous cell carcinoma of the oral cavity. Cancer Lett 2005;225:27–33.
45. Jun H. J., Ahn M. J., Kim H. S. et al. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer 2008;99(1):167–72. doi: 10.1038 / sj. bjc. 6604464.
46. Chiu T. J., Chen C. H., Chien C. Y. et al. High ERCC1 expression predicts cisplatinbased chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betelchewing area. J Transl Med 2011 Mar 23;9:31. doi: 10.1186 / 1479-5876-9-31.
47. Fillies T., Werkmeister R., van Diest P. J. et al. HIF1-alpha overexpression indicates a good prognostic in early stage squamous cell carcinomas of the oral floor. BMC Cancer 2005;5:84.
48. Jonathan R. A., Wijffels K. I., Peeters W. et al. The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON. Radiother Oncol 2006;79(3):288–97.
49. Kunkel M., Moergel M., Stockinger M. et al. Overexpression of GLUT-1 is associated with resistance to radiotherapy and adverse prognostic in squamous cell carcinoma of the oral cavity. Oral Oncol 2007;43:796–803.
50. Choi S. W., Kim J. Y., Park J. Y. et al. Expression of carbonic anhydrase IX is associated with postoperative recurrence and poor prognostic in surgically treated oral squamous cell carcinoma. Hum Pathol 2008;39(9):1317–22.
51. Janssen K. L., Haustermans K. M., Balm A. J., Begg A. C. Hypoxia in head and neck cancer: how much, how important? Head Neck 2005;27:622–38.
52. Sakata K., Someya M., Nagakura H. et al. Brachytherapy for oral tongue cancer: an analysis of treatment results with various biological markers. Jpn J Clin Oncol 2008;38:402–7.
53. Brennan P. A., Mackenzie N., Quintero M. Hypoxia-inducible factor 1 alpha in oral cancer. J Oral Pathol Med 2005;34(7):385–9.
54. van de Pol S. M., Doornaert P. A., de Bree R. et al. The significance of anemia in squamous cell head and neck cancer treated with surgery and postoperative radiotherapy. Oral Oncol 2006;42:131–8.
55. Lin P. Y., Yu C. H., Wang J. T. et al. Expression of hypoxia-inducible factor-1 alpha is significantly associated with the progression and prognostic of oral squamous cell carcinomas in Taiwan. J Oral Pathol Med 2008;37:18–25.
56. Liu S. Y., Chang L. C., Pan L. F. et al. Clinicopathologic significance of tumor celllined vessel and microenvironment in oral squamous cell carcinoma. Oral Oncol 2008;44:277–85.
57. Arcasoy M. O., Amin K., Chou S. C. et al. Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. Clin Cancer Res 2005;11:20–7.
58. Roh J. L., Cho K. J., Kwon G. Y. et al. The prognostic value of hypoxia markers in T2-staged oral tongue cancer. Oral Oncol 2009;45:63–8.
59. Chuang H. C., Su C. Y., Huang H. Y. et al. High expression of CD105 as a prognostic predictor of early tongue cancer. Laryngoscope 2006;116:1175–9.
60. Marioni G., Marino F., Giacomelli L. et al. Endoglin expression is associated with poor oncologic outcome in oral and oropharyngeal carcinoma. Acta Otolaryngol 2006;126:633–9.
61. Campbell T. N., Robbins S. M. The Eph receptor / ephrin system: an emerging player in the invasion game. Curr Issues Mol Biol 2008;10:(1–2)61–6.
62. Pasquale E. B. Eph receptor signalling casts a wide net on cell behavior. Nat Rev Mol Cell Biol 2005;6(6):462–75.
63. Shao Z., Zhang W. F., Chen X. M., Shang Z. J. Expression of EphA2 and VEGF in squamous cell carcinoma of the tongue: correlation with the angiogenesis and clinical outcome. Oral Oncol 2008;44:1110–7.
64. Wimmer-Kleikamp S. H., Lackmann M. Eph-modulated cell morphology, adhesion and motility in carcinogenesis. IUBMB Life 2005;57(6):421–31.
65. Kyzas P. A., Cunha I. W., Ioannidis J. P. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a metaanalysis. Clin Cancer Res 2005;11:1434–40.
66. Arora S., Kaur J., Sharma C. et al. Stromelysin 3, Ets-1, and vascular endothelial growth factor expression in oral precancerous and cancerous lesions: correlation with microvessel density, progression, and prognosis. Clin Cancer Res 2005;11:2272–84.
67. Chien C. Y., Su C. Y., Hwang C. F. et al. High expressions of CD105 and VEGF in early oral cancer predict potential cervical metastasis. J Surg Oncol 2006;94:413–7.
68. Shang Z. J., Li Z. B., Li J. R. VEGF is upregulated by hypoxic stimulation and related to tumour angiogenesis and severity of disease in oral squamous cell carcinoma: in vitro and in vivo studies. Int J Oral Maxillofac Surg 2006;35(6):533–8.
69. de Vicente J. C., Fresno M. F., Villalain L. et al. Expression and clinical significance of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carcinoma. Oral Oncol 2005;41(3):283–93.
70. Kim S. H., Cho N. H., Kim K. et al. Correlations of oral tongue cancer invasion with matrix metalloproteinases (MMPs) and vascular endothelial growth factor (VEGF) expression. J Surg Oncol 2006;93(4):330–7.
71. Kosunen A., Pirinen R., Ropponen K. et al. CD44 expression and its relationship with MMP-9, clinicopathological factors and survival in oral squamous cell carcinoma. Oral Oncol 2007;43(1):51–9.
72. Luukkaa M., Vihinen P., Kronqvist P. et al. Association between high collagenase-3 expression levels and poor prognostic in patients with head and neck cancer. Head Neck 2006;28(3):225–34.
73. Lyons A. J., Jones J. Cell adhesion molecules, the extracellular matrix and oral squamous carcinoma. Int J Oral Maxillofac Surg 2007;36:671–9.
74. Bouchet B. P., Caron de Fromentel C., Puisieux A., Galmarini C. M. p53 as a target for anti-cancer drug development. Crit Rev Oncol Hematol 2006;58:190–207.
75. Curran D., Giralt J., Harari P. M. et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 2007;25:2152–5.
76. Garcia-Montesinos-Perea B., ValBernal J. F., Saiz-Bustillo R. Epidermoid carcinoma of the lip: an immunohistochemical study. Med Oral Patol Oral Cir Bucal 2005;10(5):454–61.
77. Georgolios A., Batistatou A., Charalabopoulos A. et al. The role of CD44 adhesion molecule in oral cavity cancer. Exp Oncol 2006;28(2):94–8.
78. Gonzalez-Moles M. A., Gil-Montoya J. A., Ruiz-Avila I. et al. Prognostic significance of p21WAF1 / CIP1, p16INK4a and CD44s in tongue cancer. Oncol Rep 2007;18(2):389–96.
79. Lo Muzio L., Campisi G., Farina A. et al. P-cadherin expression and survival rate in oral squamous cell carcinoma: an immunohistochemical study. BMC Cancer 2005;5:63.
80. Maeda G., Chiba T., Okazaki M. et al. Expression of SIP1 in oral squamous cell carcinomas: implications for E-cadherin expression and tumor progression. Int J Oncol 2005;27:1535–41.
81. Pukkila M., Kosunen A., Ropponen K. et al. High stromal versican expression predicts unfavourable outcome in oral squamous cell carcinoma. J Clin Pathol 2007;60:267–72.
82. Rahmani M., Wong B. W., Ang L. et al. Versican: signaling to transcriptional control pathways. Can J Physiol Pharmacol 2006;84(1):77–92.
83. Ueda G., Sunakawa H., Nakamori K. et al. Aberrant expression of betaand gamma-catenin is an independent prognostic marker in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 2006;35:356–61.
84. Kyzas P. A., Denaxa-Kyza D., Ioannidis J. P. Almost all articles on cancer prognostic markers report statistically significant results. Eur J Cancer 2007;43(17):2559–79.
85. Dorsey K., Agulnik M. Promising new molecular targeted therapies in head and neck cancer. Drugs 2013;73(4):315–25.
Рецензия
Для цитирования:
Игнатова А.В., Мудунов А.М., Нариманов М.Н. ПРОГНОСТИЧЕСКОЕ ЗНАЧЕНИЕ БИОМАРКЕРОВ ПРИ ПЛОСКОКЛЕТОЧНОМ РАКЕ ПОЛОСТИ РТА. ОБЗОР ЛИТЕРАТУРЫ. Опухоли головы и шеи. 2014;(4):28-33. https://doi.org/10.17650/2222-1468-2014-0-4-28-33
For citation:
Ignatova A.V., Mudunov A.M., Narimanov M.N. PROGNOSTIC SIGNIFICANCE OF BIOMARKERS IN ORAL SQUAMOUS CELL CARCINOMA. REVIEW. Head and Neck Tumors (HNT). 2014;(4):28-33. (In Russ.) https://doi.org/10.17650/2222-1468-2014-0-4-28-33
Просмотров:
956
Послать статью по эл. почте 